Special Issue

Diabetes Mellitus: Current Research and Future Perspectives

Message from the Guest Editor

The heterogeneity in age at onset and clinical presentation within the same form of diabetes, differences in the response to treatments in patients with the same phenotype, as well as the variability in the course of the disease require personalized management. The precision medicine approach has been applied to individuals with monogenic diabetes (i.e., MODY, neonatal diabetes) and to type 1 and type 2 diabetes, to select treatments that are most likely to offer benefits and least likely to cause side effects, with improvement of clinical outcomes and economic cost saving.   In the last 10 years, genetic, metabolomic, immunologic, and other sophisticated tests have become less expensive and more widespread; therefore, it is expected that precision medicine will become increasingly applied to diabetes care. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current state of precision medicine applied to diabetes, to show some of the latest findings and future perspectives, and to integrate expertise from basic science, clinical, and population-based approaches.

Guest Editor

Dr. Roberto Franceschi

Pediatric Unit, S. Chiara Hospital, 38122 Trento, Italy

Deadline for manuscript submissions

closed (20 February 2024)

Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/journal/
jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).